We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Events

Bioxodes at WSC 2026: Final Phase 2a BIRCH Data Selected for Late-Breaking Oral Presentation

Bioxodes at WSC 2026: Final Phase 2a BIRCH Data Selected for Late-Breaking Oral Presentation
Check the link
Events
Bioxodes at WSC 2026: Final Phase 2a BIRCH Data Selected for Late-Breaking Oral Presentation

This year’s congress marks an important milestone for Bioxodes, as the final Phase 2a data from the BIRCH trial of BIOX-101 in acute intracerebral hemorrhage (ICH) have been selected for a Late-Breaking Science oral presentation. The presentation will be delivered by Dr. Dimitri Hemelsoet, neurologist at Ghent University Hospital and investigator in the BIRCH trial, and will cover the complete Phase 2a dataset, including safety, imaging, and functional outcomes through Day 360.

Presentation details

Abstract: 1056
Title: BIRCH: A Phase IIa randomized study of BIOX-101 in acute intracerebral hemorrhage
Session: Late Breaking Science Abstracts 02 – ICH, Vascular Risk & Prevention
Date: Wednesday, October 21, 2026
Time: 10:00–11:30 KST